Cargando…
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of the gastrointestinal tract. The advent of targeted kinase-inhibitors has revolutionised treatment strategies and clinical outcomes for patients with advanced GIST. In the majority of countries, sunitinib is the only a...
Autores principales: | SAPONARA, MARISTELLA, LOLLI, CRISTIAN, NANNINI, MARGHERITA, DI SCIOSCIO, VALERIO, SERRA, CARLA, MANDRIOLI, ANNA, PALLOTTI, MARIA CATERINA, BIASCO, GUIDO, PANTALEO, MARIA ABBONDANZA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156266/ https://www.ncbi.nlm.nih.gov/pubmed/25202412 http://dx.doi.org/10.3892/ol.2014.2348 |
Ejemplares similares
-
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor
por: Lolli, Cristian, et al.
Publicado: (2011) -
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib
por: Pallotti, Maria Caterina, et al.
Publicado: (2012) -
Three cases of bone metastases in patients with gastrointestinal stromal tumors
por: Di Scioscio, Valerio, et al.
Publicado: (2011) -
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2012) -
Complete radiological response to first-line regorafenib in a patient with
abdominal relapse of BRAF V600E mutated GIST
por: Nannini, Margherita, et al.
Publicado: (2020)